CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187

https://doi.org/10.5281/zenodo.15201463

https://www.iajps.com/volumes/volume12-april-2025/15-issue-04-april-25/

Available online at: http://www.iajps.com *Review Article*

EVALUATION OF THE IMPACT OF EXCIPIENTS ON THE BIOAVAILABILITY OF A POORLY SOLUBLE DRUGS

Ayan khan[1]*, Ajip A. Rathod[2], Nandkishor B. Deshmukh[3], Swati P. Deshmukh[4]

Shraddha institute of Pharmacy, Kondala zambre, Washim (mh) India 444505.
[1] Department of Pharmacy, Shraddha Institute of Pharmacy, Washim, Maharashtra, India.
[2] Department of Pharmacy, Shraddha Institute of Pharmacy, Washim, Maharashtra, India.
[3] Department of Pharmaceutics, Shraddha Institute of Pharmacy, Washim, Maharashtra, India.
[4] Department of Pharmacology, Institute of Pharmacy, Washim, Maharashtra, India.

Abstract:

The bioavailability of poorly soluble drugs is a critical concern in pharmaceutical development. One of the primary strategies to enhance drug solubility and, subsequently, bioavailability is through the use of excipients. Excipients, which are inert substances used in drug formulations, can play various roles in improving the dissolution rate and solubility of poorly soluble drugs, thereby enhancing their bioavailability. This abstract evaluates the impact of different types of excipients—such as surfactants, co-solvents, polymers, and lipid-based excipients—on the bioavailability of drugs with low aqueous solubility.

Recent studies have demonstrated that excipients can improve bioavailability by several mechanisms: enhancing drug dissolution, improving drug absorption through modulation of the gastrointestinal environment, and altering the pharmacokinetic profile of drugs.

The oral bioavailability of poorly soluble drugs, often classified as Biopharmaceutical Classification System (BCS) Class II and IV compounds, remains a key obstacle in pharmaceutical development. Inadequate solubility limits dissolution, leading to poor absorption and suboptimal drug efficacy. Excipients, non-active components in drug formulations, play a pivotal role in overcoming these limitations by modifying the drug's physicochemical properties and promoting more efficient absorption.

Keywords: *Excipients, Bioavailability enhancement, Poorly soluble drugs, Solubility enhancement, Pharmaceutical formulation, Drug absorption. Solid dispersion, Permeability enhancement, Pharmacokinetic Drug, solubilisation, Self-emulsifying, drug delivery systems (SEDDS), Bio enhancers.*

Corresponding author:
Ayan khan,
Department of Pharmacy,
Shraddha Institute of Pharmacy,
Washim, Maharashtra, India.

QR code

Please cite this article in press Ayan khan et al., Evaluation Of The Impact Of Excipients On The Bioavailability Of A Poorly Soluble Drugs., Indo Am. J. P. Sci, 2025; 12(04).

1. INTRODUCTION:

Bioavailability refers to the rate and extent to which an active pharmaceutical ingredient (API) reaches systemic circulation and becomes available at the intended site of action. It is a critical factor in drug development and clinical performance. Poorly soluble drugs often face challenges in achieving adequate bioavailability, as their low solubility can limit absorption, therapeutic efficacy, and patient outcomes. The challenge of poor solubility in drugs is one of the most significant obstacles in modern drug development, particularly for compounds classified under Biopharmaceutics Classification System (BCS) Class II and IV. These drugs exhibit low aqueous solubility, which often results in limited absorption and low bioavailability when administered orally. This presents a substantial hurdle, as oral administration is the most common and preferred route for drug delivery due to its convenience and patient compliance.

However, for drugs with poor solubility, achieving optimal therapeutic effects through oral dosing becomes problematic, necessitating innovative formulation strategies.Various excipients, such as surfactants, solubilizes, polymers, and lipids, are commonly employed to enhance the bioavailability of poorly soluble drugs. For instance, surfactants reduce surface tension and facilitate the wetting of hydrophobic drug particles, while solubilizes improve the drug's solubility in aqueous environments. Polymers and lipids can create micellar or lipid- based delivery systems that not only improve drug solubility but also protect the drug from degradation in the harsh gastrointestinal environment.

In addition, novel excipient-based approaches, such as solid dispersions, self-emulsifying drug delivery systems (SEDDS), and nanoparticles, have emerged as promising strategies to improve the solubility and, consequently, the bioavailability of poorly soluble drugs.The impact of excipients in pharmaceutical formulations is multifaceted, influencing various aspects of drug development, manufacturing, and patient outcomes [1].

2. Key Impacts of Excipients:

Drug Stability: Excipients can enhance the stability of the active pharmaceutical ingredient (API), protecting it from degradation due to environmental factors like moisture, light, or oxygen. This stability is crucial for ensuring the drug maintains its efficacy throughout its shelf life.

Bioavailability: The choice of excipients can significantly affect the solubility and absorption of the API in the body, impacting its bioavailability. For example, surfactants can improve solubility, while binders can influence the dissolution rate of solid dosage forms.

Release Profile: Excipients play a critical role in controlling the release of the drug from the dosage form. They can be used to create immediate-release, controlled-release, or sustained- release formulations, thereby affecting the therapeutic effect and patient adherence.

Manufacturing Process: Excipients can influence the manufacturability of drug products. Their physical and chemical properties can affect processes like granulation, compression, and coating, which are essential for producing consistent and high-quality formulations.

Patient Compliance and Acceptability: Excipients can improve the sensory attributes of drugs (taste, odour, appearance), making them more acceptable to patients, especially children and the elderly. This can enhance patient compliance with prescribed therapies [2].

3. Mechanism of Bioavailability Enhancement:

There are various techniques available to improve the solubility of poorly soluble drugs. Some of the approaches to improve the solubility are:

3.1. pH Adjustment:

The assimilation of sedate is generally dependent upon dissemination, which changes with pH of the person locales inside the gastrointestinal tract, the pKa of the medicate and penetrability, which are not as it were moderated by the surface zone of the locale in which it is discharged, but moreover the territorial pH impacts upon sedate ionization. By applying a pH alter, ineffectively water dissolvable drugs with parts of the particle that can be protonated (base) or deprotonated (corrosive) may potentially be broken down in water. Because blood is a solid buffer, upon intravenous organization the ineffectively solvent drug may be accelerate with pH between 7.2 – 7.4.

3.2. Particle size reduction:

Drug bioavailability is one of the most important measures of effectiveness and it is often determined by the drug or delivery formulation's optimal particle size. For formulation purposes, a dispersion of smaller particles may favourably enhance the drug's active surface area to allow for more broad formulation strategies and delivery systems. Thermal stress can be, on the other hand, significant when dealing with particles in suspension and aerosols

spraying which are also common drug development technique but also known to cause degradation. These particular development pathways are unable to work for prescription drugs with powdered forms having particle sizes/listing of less than <0.1mg/mL.

3.3. Complexation:

The lipophilic drug-cyclodextrin complexes also termed as inclusion complexes can be achieved just by mixing the drug and excipients together as it aims at enhancing drug solubilization. The technique of forming inclusion complexes has, in spite of all the other approaches developed to enhance the solubility of drugs, solvents the most specifically designed to overcome the inadequately soluble areas of the drugs to be delivered. Cyclodextrins (CD) are circular oligosaccharides with hydrophilic outer surface and hydrophobic cavities formed from a number of glucose molecules and arranged in a ring. The inclusion complex is formed when a nonpolar molecule or a non-polar part of a molecule, which is known as a guest, gets inserted into the cavity of another molecule or a group of molecules, which is known as the host [3].



Fig: Techniques Using Multifunctional Excipients

4. Excipients Drug Interaction:

Excipient-drug interactions can significantly impact the efficacy, safety, and stability of pharmaceutical products.

4.1. Types of Excipient-Drug Interactions:

1. **Chemical interactions:** Chemical reactions between excipients and drugs.

2. **Physical interactions:** Changes in physical properties, such as solubility or dissolution.

3. **Physiological interactions:** Physiological response to drugs, potentially altering their therapeutic outcomes.

4.1.1. Chemical Drug Excipients Interaction:

Chemical interactions for the pharmaceutical ingredients are mostly divided into the following sections:

a. Hydrolysis:

The presence of an aqueous environment in the formulation of pharmaceutical can make esters, amides, lactones or lactams present in it, get hydrolysed. This process is termed as the most frequently expected cause of drug degradation among dosage forms of pharmaceuticals where water is present. Such hydrolysis of esters in pharmaceutical formulation most probably will be assisted by the acidic or basic environment; an acidic environment will take this de- esterification to equilibrium while basic media will take it to completion. Under chemical hydrolysis pH 1.2 and pH 10, eslicarbazepine-acetate is converted into the active form eslicarbazepine.

b. Oxidation:

Oxidative degradation occurs when APIs, particularly those with functional groups like hydroxyl or amine groups, interact with excipients that promote oxidation. Common excipients like polyethylene glycol (PEG) and starch can introduce peroxides, which act as catalysts for oxidation. This results in the degradation of susceptible drugs such as vitamins, catecholamine's, or steroids.

Example: PEG, often used as a plasticizer or solvent, can degrade under certain conditions, generating peroxides that oxidize drugs like ascorbic acid or epinephrine.

c. pH Alteration:

Excipients can alter the micro environmental pH within a formulation, impacting drug stability. Alkaline excipients (e.g., magnesium stearate) or acidic excipients (e.g., citric acid) can induce degradation pathways like hydrolysis or oxidation. pH-sensitive drugs, such as beta-lactam antibiotics or macrolides, are particularly vulnerable to such changes.

Example: Magnesium stearate, often used as a lubricant, can increase the local pH, promoting the degradation of acid-sensitive drugs like erythromycin [4].

4.1.2. Physical Drug Excipients Interaction:

Physical drug-excipient interactions do not involve chemical reactions but are often driven by changes in physical states, molecular interactions, or processes like adsorption, agglomeration, and phase separation. These interactions can affect the formulation's mechanical, flow, and dissolution properties.

a. Adsorption:

Adsorption occurs when the drug molecules bind to the surface of excipients, which can significantly impact the drug's availability for absorption. This type of interaction is common with excipients that have a large surface area (e.g., colloidal silicon dioxide) or possess surface- active properties (e.g., magnesium stearate).

Impact: Adsorption of drugs onto excipient surfaces can reduce the free drug concentration, lowering bioavailability. It may also cause drug precipitation or retard drug release from formulations.

Example: Colloidal silicon dioxide, used as a flow agent, can adsorb APIs on its large surface area, altering the dissolution rate and bioavailability of drugs like poorly soluble statins.

b. Agglomeration and Particle Size Effects:

The size and shape of particles of both the API and excipients can significantly influence drug- excipient interactions. Particle size reduction during manufacturing (e.g., milling) increases the surface area, which may enhance or inhibit interactions between the drug and excipients.

Impact: Fine particles may agglomerate, reducing the flow properties of powders. Agglomeration can lead to inconsistent mixing and tablet uniformity, which may affect the dosage accuracy and dissolution behavior of the drug.

Example: In inhalation formulations, micronized drugs with small particle sizes may agglomerate, reducing dispersion efficiency and impacting drug delivery to the lungs

c. Polymorphic Transitions:

Some drugs exist in multiple crystalline forms (polymorphs), which have different physical properties such as solubility and melting points. Physical interactions with excipients during manufacturing processes, such as grinding, compression, or exposure to moisture, can induce polymorphic transformations, impacting the drug's stability and bioavailability.

Impact: A polymorphic transition from a more stable to a less stable form can lead to reduced solubility, affecting the drug's dissolution rate and absorption. In extreme cases, the drug may convert to an amorphous

form, which is typically more soluble but less stable.
Example: The anti-inflammatory drug indomethacin is known to undergo polymorphic transitions under mechanical stress, such as during tableting, leading to changes in its dissolution properties [5].

4.1.3. Physiological /Therapeutic Drug Excipients Interaction:

The interactions between excipients and the physiological environment can occur through various mechanisms. These include altering the absorption rate of the drug, modulating the drug's metabolism, influencing drug distribution, and affecting drug elimination. Furthermore, some excipients may provoke immune or gastrointestinal responses that could alter the therapeutic outcome.

a. Permeation Enhancement:
Some excipients, particularly surfactants, permeation enhancers, and solubilizers, can enhance the absorption of drugs by altering the structure or function of biological membranes, such as the intestinal epithelium. These excipients increase the permeability of cell membranes, allowing for more efficient drug transport across the gut barrier or through the skin in topical formulations.
Example: Sodium lauryl sulphate (SLS) is commonly used as a surfactant in oral formulations and can increase the permeability of the intestinal mucosa, enhancing the absorption of poorly soluble drugs.

b. Modification of Drug Dissolution:
Excipients such as disintegrants and solubilizers can modify the dissolution rate of the drug in the gastrointestinal tract, impacting its absorption profile. Disintegrants accelerate the breakdown of solid dosage forms, while solubilizers increase the solubility of hydrophobic drugs, allowing for more rapid absorption.
Example: Polyethylene glycol (PEG) can enhance the dissolution of poorly water-soluble drugs like ibuprofen, improving their absorption in the gastrointestinal tract.

c. Interaction with Transport Proteins:
Excipients can interact with drug transporters, such as P-glycoprotein (P-gp) and other ATP- binding cassette (ABC) transporters, which are responsible for drug efflux from cells. Some excipients inhibit these transporters, increasing drug absorption and bioavailability.
Example: Polysorbate 80, a common surfactant used in injectable and oral formulations, can inhibit P-glycoprotein-mediated drug efflux, leading to increased bioavailability of drugs like paclitaxel [6].

5. Case Studies:

Improving the bioavailability of poorly soluble drugs is a critical area of pharmaceutical development. Excipients play a vital role in enhancing the solubility and absorption of these drugs, allowing for more effective oral drug delivery. Below are case studies that explore different excipients used to improve the bioavailability of poorly soluble drugs:

5.1. Case Study: Use of Cyclodextrins for Solubility Enhancement:

Drug: Itraconazole (an antifungal agent)

Excipients: Hydroxypropyl-β-cyclodextrin (HP-β-CD)

Mechanism: Cyclodextrins form inclusion complexes with poorly soluble drugs, increasing the aqueous solubility and dissolution rate.
Outcome: The formulation of itraconazole with HP-β-CD significantly improved the drug's solubility and bioavailability.
Application: Cyclodextrins are widely used in drug formulations where solubility is a limiting factor [7].

5.2. Case Study: Use of Lipid-Based Excipients in Self-Emulsifying Drug Delivery Systems (SEDDS):

Drug: Fenofibrate (used to treat hypercholesterolemia)

Excipients: Lipid-based excipients (e.g., triglycerides, surfactants like Polysorbates 80)

Mechanism: SEDDS enhances drug absorption by forming fine oil-in-water emulsions in the gastrointestinal tract, increasing the surface area for drug absorption.
Outcome: The lipid-based formulation of fenofibrate resulted in a significant increase in bioavailability compared to the conventional formulation.
Application: Lipid-based excipients are especially beneficial for drugs with poor water solubility, offering improved dissolution and absorption [8].

5.3. Case Study: Solid Dispersion Techniques with Polymer Excipients:

Drug: Nifedipine (a calcium channel blocker for hypertension)

Excipients: Polyvinylpyrrolidone (PVP), polyethylene glycol (PEG)

Mechanism: Solid dispersion enhances solubility by dispersing the drug at the molecular level within a polymer matrix, thereby improving dissolution.
Outcome: Nifedipine's bioavailability was significantly improved when formulated as a solid dispersion with PVP, resulting in faster onset of action.
Application: Solid dispersion with polymers like PVP and PEG is a common strategy to improve the

dissolution rate of poorly soluble drugs [9].

6. Challenges Using Excipients:

Excipients are inactive substances used as carriers for the active ingredients of a medication. Although they are generally considered inert, there are several challenges associated with their use in pharmaceutical formulations. Some of the key challenges include:

6.1. Compatibility with Active Ingredients:

Excipients may chemically interact with active pharmaceutical ingredients (APIs), leading to reduced drug efficacy or stability. These interactions can result in degradation, altered release rates, or other unintended consequences.

6.2. Allergenicity and Toxicity:

Some excipients can cause allergic reactions or toxic effects in certain populations. For example, lactose is commonly used as an excipient but can cause issues for people with lactose intolerance. Similarly, preservatives, dyes, or flavouring's can trigger hypersensitivity reactions.

6.3. Regulatory and Safety Concerns:

Regulatory requirements for excipients can vary across countries, which can complicate global drug development. Additionally, safety profiles of excipients need to be thoroughly assessed, particularly in special populations like children, elderly patients, or those with compromised health.

6.4. Impact on Drug Release and Bioavailability:

Excipients can affect the release and absorption of the active drug in the body. Poor selection or improper use of excipients might lead to issues with bioavailability, delayed or inconsistent release, or drug instability.

6.5. Manufacturing Challenges:

Some excipients may present challenges during the manufacturing process, such as sensitivity to moisture, heat, or light. This can lead to difficulties in maintaining batch consistency and stability over time [10-12].

7. Future Perspectives in Excipients and Poorly Soluble Drugs:

The pharmaceutical industry is constantly evolving, with significant research directed towards improving drug delivery systems. One of the most critical challenges is enhancing the bioavailability of poorly soluble drugs. These drugs, which make up approximately 40% of the newly developed chemical entities, pose significant challenges in formulation. Excipients play a vital role in addressing this issue, as they are the inactive components of a drug formulation that can enhance solubility, stability, and bioavailability. The future perspectives of excipients and poorly soluble drugs revolve around advanced formulation strategies, novel excipients, and technologies that can transform drug development.

7.1. Emerging Formulation Strategies:

Several advanced formulation approaches have emerged to improve the solubility and bioavailability of poorly soluble drugs. These techniques include:

a. Techniques:

Solid dispersions are mixtures of poorly soluble drugs with a carrier matrix that helps in enhancing solubility. The drug is dispersed in a solid matrix, usually polymers, which helps to increase the dissolution rate. Recent innovations in solid dispersion include the use of amorphous solid dispersions (ASDs), where the drug exists in an amorphous form that is more soluble than its crystalline counterpart. This technique is becoming more prevalent with advancements in spray drying, hot melt extrusion, and freeze-drying techniques.

b. Nanotechnology in Drug Delivery:

Nanotechnology has emerged as a promising solution to overcome poor solubility by reducing particle size to the nanometer scale. Techniques like nanocrystals, nanosuspensions, and nanoemulsions are being used to increase the surface area and solubility of poorly soluble drugs. These technologies allow for controlled drug release, enhanced absorption, and improved bioavailability. Lipid-based nanocarriers, such as solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), have gained attention for their ability to encapsulate poorly soluble drugs and protect them from degradation.

c. Lipid-Based Drug Delivery Systems:

Lipid-based formulations such as self-emulsifying drug delivery systems (SEDDS) and liposomes are gaining popularity in enhancing the solubility of poorly soluble drugs. These formulations promote the dissolution of drugs in the gastrointestinal (GI) tract by forming micelles or emulsions that can increase the solubility and absorption of lipophilic drugs. SEDDS, in particular, have been used in various commercial products, with continuous innovations in the development of new lipid excipients [13-14].

7.2. Development of Novel Excipients:

The future of excipients is focused on the discovery of novel excipients that are specifically designed to enhance the solubility, stability, and bioavailability of poorly soluble drugs. These new excipients can play multiple roles, such as solubilizers, surfactants, and stabilizers.

a. Functional Excipients:

One area of research is the development of multifunctional excipients, which combine properties of different traditional excipients into a single compound. For instance, copolymers, such as poloxamers and cellulosic derivatives, exhibit surfactant properties and can form micelles to increase solubility. Additionally, they have stabilizing effects, making them ideal for drugs prone to

degradation.

b. Cyclodextrins:

Cyclodextrins are cyclic oligosaccharides that have been widely used to improve drug solubility by forming inclusion complexes with poorly soluble drugs. They can encapsulate the drug within their hydrophobic core, enhancing its dissolution in aqueous environments. Advances in the use of modified cyclodextrins, such as hydroxypropyl-β-cyclodextrin, have shown increased solubilizing effects with improved safety profiles.

c. Surfactants and Solubilizers:

Surfactants are another class of excipients that reduce surface tension and improve the solubility of poorly soluble drugs. Novel surfactants, such as vitamin E TPGS (D-alpha- tocopheryl polyethylene glycol 1000 succinate), have gained traction due to their ability to improve both solubility and absorption. In addition to surfactants, solubilizing agents like polyethylene glycols (PEGs) and polyvinylpyrrolidones (PVPs) are being studied for their potential in enhancing solubility and ensuring drug stability [15].

8. REFERENCE:

1. Sharma, P., & Gupta, S. (2020) Formulation strategies to enhance the solubility and bioavailability of poorly soluble drugs. Journal of Pharmaceutical Sciences, 109(2), 573-587.
2. Baker, R. W., & Lonsdale, H. K. (2021) The role of excipients in drug solubility enhancement. Pharmaceutical Research, 38(4), 705-724.
3. Patel, K., & Vohra, S. (2019) Influence of excipients on the solubility and stability of poorly soluble drugs: A review. Current Drug Delivery, 16(7), 834-846.
4. Brahmankar, D. M., & Jaiswal, S. B. (2018) Bioavailability enhancement of poorly soluble drugs using novel excipients. Drug Development and Industrial Pharmacy, 44(5), 713-725.
5. Meyer, M. R., & Stangier, J. (2020) The effects of excipients on the solubility of poorly soluble drugs. European Journal of Pharmaceutical Sciences, 150, 105329.
6. Zhang, Y., & Liu, Z. (2019) Nanocrystals for enhancing oral bioavailability of poorly soluble drugs: The role of excipients. International Journal of Nano medicine, 14, 5757-5772.
7. Sharma, S., & Chaudhary, S. (2021) Formulation techniques for enhancing the bioavailability of poorly soluble drugs: A review. Pharmaceutics, 13(3), 400.
8. Rathi, A., & Dey, P. (2020) Impact of excipients on the dissolution and bioavailability of poorly soluble drugs. Asian Journal of Pharmaceutical Sciences, 15(4), 400-412.
9. Saini, S., & Kaur, G. (2018) Role of excipients in enhancing the bioavailability of poorly soluble drugs. Current Drug Metabolism, 19(6), 546-556.
10. Devi, S. G., & Paul, S. (2022) Use of surfactants and polymers in the formulation of poorly soluble drugs. International Journal of Pharmaceutical Sciences and Research, 13(8), 3055- 3068.
11. Ghosh, A., & Sen, K. (2021) Evaluation of excipient effects on the solubility and bioavailability of hydrophobic drugs. *Journal of Drug Delivery Science and Technology, 61, 102195.
12. Patil, S. B., & Gajbhiye, V. (2020). Excipients in drug formulation: Their impact on bioavailability. Journal of Controlled Release, 321, 333-345.
13. Adhikari, S., & Bansal, A. (2021) A review of excipient-based strategies for improving the bioavailability of poorly soluble drugs. Journal of Pharmaceutical Innovation, 16(3), 455-467.
14. Chaudhary, S. K., & Gupta, P. (2021) Excipient selection for poorly soluble drug formulations: A comprehensive review. International Journal of Pharmaceutics, 599, 120420.
15. Kumar, S., & Verma, R. (2019) Novel excipients for drug solubilization: Impact on bioavailability. Journal of Drug Delivery Science and Technology, 53, 101-115.